RARE

#1846
Ultragenyx Pharmaceutical Inc.
24.57 USD
+3.98%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
24.57
24.57
Rango anual
18.29
42.37
Cambio diario
+3.98%
Variación mensual
+13.91%
Variación en los últimos 6 meses
-22.66%
Cambio anual
-29.72%
Cierres anteriores
23.63
Abrir
24.57
Bid
Ask
Mínimo
24.57
High
24.57
Volumen
97
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 2.37 B
  • Employee 1 371
  • Founded 2010
  • CEO Emil Kakkis
  • Website www.ultragenyx.com
  • Headquarter Delaware, United States
  • FIGI BBG001RWPDW6
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-3.95
Relación precio/flujo de caja
3.37

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA.

Noticias